Eperezolid
Chemical compound
- none
- (S)-N-[[3-[3-Fluoro-4-[4-(2-hydroxyacetyl)piperazin-1-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
- 165800-04-4 Y
- 73214
- 65969 N
- C460ZSU1OW
- D04017 Y
- ChEMBL47955 N
- DTXSID50168028
- Interactive image
- CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCN(CC3)C(=O)CO)F
InChI
- InChI=1S/C18H23FN4O5/c1-12(25)20-9-14-10-23(18(27)28-14)13-2-3-16(15(19)8-13)21-4-6-22(7-5-21)17(26)11-24/h2-3,8,14,24H,4-7,9-11H2,1H3,(H,20,25)/t14-/m0/s1 N
- Key:SIMWTRCFFSTNMG-AWEZNQCLSA-N N
Eperezolid is an oxazolidinone antibiotic.[citation needed]
Synthesis
See also
- Linezolid
References
- ^ Brickner SJ, Hutchinson DK, Barbachyn MR, Manninen PR, Ulanowicz DA, Garmon SA, et al. (February 1996). "Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections". Journal of Medicinal Chemistry. 39 (3): 673–9. doi:10.1021/jm9509556. PMID 8576909.
- v
- t
- e
Aminoglycosides (initiation inhibitors) |
| ||||||
---|---|---|---|---|---|---|---|
Tetracycline antibiotics (tRNA binding) |
|
Steroid antibacterials |
---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e